- Home
- FOLD
as 07-26-2024 4:00pm EST
Amicus Therapeutics Inc is a biotechnology company focused on discovering, developing and delivering medicines for people living with rare metabolic diseases. The company is engaged in developing a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. It has a portfolio of product opportunities, including oral precision medicine for people living with Fabry disease who have amenable genetic variants; a clinical-stage, treatment paradigm for Pompe disease, and a rare disease gene therapy portfolio. The company has one segment focused on the discovery, development, and commercialization of advanced therapies to treat a range of devastating rare and orphan diseases.
| Founded: | 2002 | Country: | United States |
| Employees: | N/A | City: | PHILADELPHIA |
| Market Cap: | 3.0B | IPO Year: | 2007 |
| Target Price: | $17.14 | AVG Volume (30 days): | 2.5M |
| Analyst Decision: | Buy | Number of Analysts: | 8 |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.49 | EPS Growth: | N/A |
| 52 Week Low/High: | $9.02 - $14.57 | Next Earning Date: | 08-06-2024 |
| Revenue: | $423,489,000 | Revenue Growth: | 25.74% |
| Revenue Growth (this year): | 30.36% | Revenue Growth (next year): | 25.78% |
Stock Insider Trading Activity of Amicus Therapeutics Inc. (FOLD)
| Name | Ticker | Relationship | Date | Transaction | Cost Per Share | Shares | Total Value | Securities Owned After Transaction(s) | SEC Form 4 |
|---|---|---|---|---|---|---|---|---|---|
| Campbell Bradley L | FOLD | President and CEO | Jul 5 '24 | Sell | $10.00 | 6,100 | $61,029.28 | 886,654 | SEC Form 4 |
| Campbell Bradley L | FOLD | President and CEO | Jul 1 '24 | Sell | $10.00 | 1,400 | $14,002.94 | 886,654 | SEC Form 4 |
| Campbell Bradley L | FOLD | President and CEO | Jun 3 '24 | Sell | $10.00 | 7,500 | $75,000.00 | 886,654 | SEC Form 4 |
| Campbell Bradley L | FOLD | President and CEO | May 1 '24 | Sell | $10.07 | 7,500 | $75,523.50 | 886,654 | SEC Form 4 |
| Campbell Bradley L | FOLD | President and CEO | Apr 1 '24 | Sell | $11.67 | 7,500 | $87,495.75 | 886,654 | SEC Form 4 |
| MCGLYNN MARGARET G | FOLD | Director | Mar 4 '24 | Sell | $13.29 | 7,500 | $99,675.00 | 59,289 | SEC Form 4 |
| MCGLYNN MARGARET G | FOLD | Director | Mar 4 '24 | Sell | $13.40 | 7,500 | $100,500.00 | 59,289 | SEC Form 4 |
| Campbell Bradley L | FOLD | President and CEO | Mar 1 '24 | Sell | $13.14 | 15,833 | $208,017.12 | 871,219 | SEC Form 4 |
| Crowley John F | FOLD | Executive Chairman | Mar 1 '24 | Sell | $13.35 | 29,181 | $389,543.01 | 573,478 | SEC Form 4 |
| Campbell Bradley L | FOLD | President and CEO | Feb 15 '24 | Sell | $14.00 | 4,167 | $58,338.00 | 871,219 | SEC Form 4 |
| Clark David Michael | FOLD | Chief People Officer | Feb 15 '24 | Sell | $14.00 | 4,427 | $61,978.00 | 253,664 | SEC Form 4 |
| Crowley John F | FOLD | Executive Chairman | Feb 15 '24 | Sell | $13.81 | 31,614 | $436,551.40 | 697,628 | SEC Form 4 |
| Rosenberg Ellen | FOLD | Chief Legal Officer | Feb 6 '24 | Sell | $13.00 | 400 | $5,200.00 | 367,654 | SEC Form 4 |
| Rosenberg Ellen | FOLD | Chief Legal Officer | Feb 6 '24 | Sell | $13.00 | 29,600 | $384,817.76 | 367,654 | SEC Form 4 |
| Campbell Bradley L | FOLD | President and CEO | Feb 1 '24 | Sell | $12.56 | 15,833 | $198,857.73 | 875,386 | SEC Form 4 |
| Crowley John F | FOLD | Executive Chairman | Feb 1 '24 | Sell | $12.62 | 31,614 | $398,918.10 | 750,838 | SEC Form 4 |
| Crowley John F | FOLD | Executive Chairman | Jan 22 '24 | Sell | $12.36 | 55,327 | $683,957.91 | 782,452 | SEC Form 4 |
| Crowley John F | FOLD | Executive Chairman | Jan 16 '24 | Sell | $12.78 | 31,614 | $404,105.96 | 837,779 | SEC Form 4 |
| Crowley John F | FOLD | Executive Chairman | Jan 9 '24 | Sell | $13.65 | 31,614 | $431,452.07 | 927,013 | SEC Form 4 |
| Crowley John F | FOLD | Executive Chairman | Jan 9 '24 | Sell | $13.65 | 31,614 | $431,452.07 | 869,393 | SEC Form 4 |
| Clark David Michael | FOLD | Chief People Officer | Jan 8 '24 | Sell | $14.00 | 8,726 | $122,164.00 | 268,089 | SEC Form 4 |
| Clark David Michael | FOLD | Chief People Officer | Jan 8 '24 | Sell | $14.00 | 1,384 | $19,376.00 | 266,705 | SEC Form 4 |
| Prout Samantha | FOLD | Chief Accounting Officer | Jan 8 '24 | Sell | $14.00 | 30,767 | $430,827.22 | 82,290 | SEC Form 4 |
| Prout Samantha | FOLD | Chief Accounting Officer | Jan 8 '24 | Sell | $14.00 | 1,337 | $18,718.00 | 80,953 | SEC Form 4 |
| Campbell Bradley L | FOLD | President and CEO | Jan 2 '24 | Sell | $14.24 | 7,500 | $106,768.50 | 947,805 | SEC Form 4 |
Latest Amicus Therapeutics Inc. News
FOLD Breaking Stock News: Dive into FOLD Ticker-Specific Updates for Smart Investing
Zacks
a month ago
Do Options Traders Know Something About Amicus (FOLD) Stock We Don't?
Simply Wall St.
2 months ago
Returns On Capital At B&S Group (AMS:BSGR) Paint A Concerning Picture
AFP
2 months ago
Seoul says it will resume loudspeaker propaganda against North
Simply Wall St.
2 months ago
It Might Not Be A Great Idea To Buy PATRIZIA SE (ETR:PAT) For Its Next Dividend
Simply Wall St.
2 months ago
OUTsurance Group Insiders Placed Bullish Bets Worth R25.5m
Barrons.com
2 months ago
Fed Meeting, Inflation Report, Apple’s WWDC, Broadcom Earnings, and More to Watch This Week
Simply Wall St.
2 months ago
Just Three Days Till BREMER LAGERHAUS-GESELLSCHAFT -Aktiengesellschaft von 1877- (FRA:BLH) Will Be Trading Ex-Dividend
Simply Wall St.
2 months ago
An Intrinsic Calculation For ORIOR AG (VTX:ORON) Suggests It's 35% Undervalued
Compare FOLD vs Leading Stocks
Share on Social Networks:
Disclaimer
The information presented on this page, "FOLD Amicus Therapeutics Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.